Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 04/24 08:20:59 pm
156.405 USD   -2.18%
04:30pShire receives new bid from Takeda as takeover deadline looms
RE
04:27pShire receives new bid from Takeda as takeover deadline looms
RE
09:54aBIOCENTURY - MA : Probiodrug, Alder
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Allergan : Allergans Botox gets US FDA green light to treat forehead lines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 04:15pm CEST

Allergan PLC (NYSE:AGN) has received the US Food and Drug Administration (FDA) approval for the use of Botox for the temporary improvement of moderate-to-severe forehead lines.

The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas. It has already been approved for the treatment of "crow`s feet" and glabellar lines.

In a statement released today announcing the FDA approval, David Nicholson, the companys chief research and development officer said: Allergan recognizes that forehead lines are a top area of concern for patients.

(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
04:30pShire receives new bid from Takeda as takeover deadline looms
RE
04:27pShire receives new bid from Takeda as takeover deadline looms
RE
09:54aBIOCENTURY - MANAGEMENT TRACKS : Probiodrug, Alder
AQ
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20LONDON MARKETS : FTSE 100 Ends At 11-week High As Pound Falls On BOE Rate-hike D..
DJ
04/20ALLERGAN : Showcases Leadership in Neurosciences with 25 Presentations at the Am..
PU
04/20Shire rejects third Takeda bid, Allergan mulling offer
AQ
04/20Shire rejects third Takeda bid, as Allergan drops out
AQ
04/20Shire Attracts Flurry Of Suitors -- WSJ
DJ
04/19Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
More news
News from SeekingAlpha
08:38aPremarket analyst action - healthcare 
02:48aIf Takeda Walks Then Shire Could Crater 
04/23SYNERGY PHARMACEUTICALS : Best Drug + Terrible Management = Terrible Investment 
04/23Unity Biotechnology Finalizes $85 Million IPO Terms 
04/23BIOTECH FORUM : The Week Ahead 
Financials ($)
Sales 2018 15 225 M
EBIT 2018 7 285 M
Net income 2018 -908 M
Debt 2018 23 926 M
Yield 2018 1,82%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,17x
EV / Sales 2019 4,83x
Capitalization 54 802 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 208 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-3.10%54 802
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571